IP Library › Granted Patent US 12,383,539
Granted Patent B2
US 12,383,539 · App. 17/282,730 · Granted Aug 12, 2025

Treating essential tremor using (R)-2-(4-Isopropylphenyl)-N-(1-(5-(2,2,2-Trifluoroethoxy)pyridin-2-yl)ethyl)acetamide

Inventors: Margaret Scott Lee (Middleton, MA); Spyridon Papapetropoulos (Wellesley, MA); Michelle S. Higgin (Holly Springs, NC); Muralikrishna Duvvuri (Chapel Hill, NC); Bruce N. Rehlaender (Cary, NC); Evan Newbold (Charlottesville, VA)
Assignee: Cavion, Inc.
A61K31/4412A61K9/0053A61K31/44A61P25/08A61P25/14A61P25/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,383,539
App. No.
17/282,730
Granted
Aug 12, 2025
Kind
B2
Abstract

This invention relates to methods and materials for treating mammals having, or at risk of developing, one or more movement disorders (e.g., essential tremor, epilepsy, and/or Parkinson's disease). For example, compositions including one or more T-type calcium channel antagonists (e.g., one or more Cav3 antagonists such as CX-8998) are provided, as well as methods for administering such compositions to a mammal having, or at risk of developing, one or more movement disorders (e.g., essential tremor, epilepsy, and/or Parkinson's disease) to treat the mammal.

Claims (76)

1. An oral dosage form comprising a Cav3 antagonist, wherein the Cav3 antagonist is CX-8998

or a pharmaceutically acceptable salt thereof,

wherein the oral dosage forms comprises a controlled release component comprising said Cav3 antagonist, and wherein the oral dosage form optionally contains an immediate release component comprising said Cav3 antagonist;

wherein said oral dosage form, when administered once daily to a human, is effective to maintain a maximum plasma concentration (Cmax) of said Cav3 antagonist divided by a mean plasma concentration of said Cav3 antagonist at 24 hours after administration

(

Cmax

plasma

⁢

⁢

concentration

⁢

⁢

at

⁢

⁢

24

⁢

⁢

hours

)

from about 1.0 to about 4.0.

2. The oral dosage form of claim 1 , wherein said human has been fasted for at least 4 hours prior to being administered said oral dosage form.

3. The oral dosage form of claim 1 , wherein said oral dosage form, when administered once daily to said human, is effective to maintain a plasma concentration of said Cav3 antagonist of above a minimum effective concentration (MEC) of said Cav3 antagonist for at least about 15 hours, wherein said minimum effective concentration is about 200 nM.

4. The oral dosage form of claim 1 , wherein said oral dosage form, when administered once daily to said human, is effective to maintain a plasma concentration of said Cav3 antagonist of above a minimum effective concentration (MEC) of said Cav3 antagonist for at least about 18 hours, wherein said minimum effective concentration is about 200 nM.

5. The oral dosage form of claim 1 , wherein said oral dosage form, when administered once daily to said human, is effective to maintain a plasma concentration of said Cav3 antagonist of above a minimum effective concentration (MEC) of said Cav3 antagonist for at least about 24 hours, wherein said minimum effective concentration is about 200 nM.

6. The oral dosage form of claim 3 , wherein said plasma concentration of said Cav3 antagonist is a plasma concentration at steady state.

7. The oral dosage form of claim 1 , wherein said oral dosage form, when administered once daily to said human, is effective to maintain a mean plasma concentration of said Cav3 antagonist from about 400 nM to about 1000 nM for at least about 12 hours.

8. The oral dosage form of claim 1 , wherein said oral dosage form, when administered once daily to said human, is effective to maintain a mean plasma concentration of said Cav3 antagonist from about 400 nM to about 1000 nM for at least about 15 hours.

9. The oral dosage form of claim 1 , wherein said oral dosage form, when administered once daily to said human, is effective to maintain a mean plasma concentration of said Cav3 antagonist from about 400 nM to about 1000 nM for at least about 18 hours.

10. The oral dosage form of claim 7 , wherein said oral dosage form, when administered once daily to said human, is effective to achieve said mean plasma concentration of said Cav3 antagonist in less than about 60 minutes.

11. The oral dosage form of claim 1 , wherein said maximum plasma concentration (Cmax) of said Cav3 antagonist is less than about 1800 nM.

12. The oral dosage form of claim 1 , wherein said maximum plasma concentration (Cmax) of said Cav3 antagonist is from about 900 nM to about 1800 nM.

13. The oral dosage form of claim 1 , wherein said maximum plasma concentration (Cmax) of said Cav3 antagonist is from about 1200 nM to about 1800 nM.

14. The oral dosage form of claim 1 , wherein said Cav3 antagonist is a hydrochloride salt.

15. The oral dosage form of claim 1 , wherein the oral dosage form comprises a controlled release component comprising said Cav3 antagonist, and wherein the oral dosage form contains an immediate release component comprising said Cav3 antagonist.

16. The oral dosage form of claim 1 , wherein said oral dosage form, when administered once daily to a human, is effective to maintain said maximum plasma concentration (Cmax) of said Cav3 antagonist divided by said mean plasma concentration of said Cav3 antagonist at 24 hours after administration

(

Cmax

plasma

⁢

⁢

concentration

⁢

⁢

at

⁢

⁢

24

⁢

⁢

hours

)

from about 1.0 to about 3.0.

17. An oral dosage form comprising CX-8998, or a pharmaceutically acceptable salt thereof, wherein the oral dosage form comprises a first component that is formulated for delayed and/or sustained release of CX-8998 and a second component that is formulated for immediate release of CX-8998.

18. The oral dosage form according to claim 17 , wherein CX-8998 is in the form of a hydrochloride salt.

19. The oral dosage form according to claim 17 , wherein the oral dosage form includes about 40% of the first component formulated for delayed and/or sustained release of CX-8998 and about 60% of the second component formulated for immediate release of CX-8998.

20. The oral dosage form according to claim 17 , wherein the CX-8998 is present in an amount of from about 0.5% to about 10% by weight of the free base equivalent of CX-8998.

21. The oral dosage form according to claim 17 , wherein the first component comprises particles coated with a pH-sensitive enteric polymer.

22. A controlled release pharmaceutical composition comprising:

CX-8998, or a pharmaceutically acceptable salt thereof; and

at least one pharmaceutically acceptable excipient, wherein the at least one pharmaceutically acceptable excipient is lactose monohydrate; crospovidone; citric acid; or sodium lauryl sulfate.

23. The pharmaceutical composition according to claim 22 , wherein the at least one pharmaceutically excipient is lactose monohydrate.

24. The pharmaceutical composition according to claim 22 , wherein the at least one pharmaceutically excipient is crospovidone.

25. The pharmaceutical composition according to claim 22 , wherein the at least one pharmaceutically excipient is citric acid.

26. The pharmaceutical composition according to claim 22 , wherein the at least one pharmaceutically excipient is sodium lauryl sulfate.

27. The pharmaceutical composition according to claim 22 , wherein the pharmaceutical composition comprises:

CX-8998, or a pharmaceutically acceptable salt thereof;

lactose monohydrate;

crospovidone;

citric acid; and

sodium lauryl sulfate.

28. The pharmaceutical composition according to claim 22 , wherein the controlled release composition comprises a first component that is formulated for delayed and/or sustained release of CX-8998 and, optionally, a second component that is formulated for immediate release of CX-8998.

29. The pharmaceutical composition according to claim 28 , wherein the oral dosage form comprises about 40% of the first component that is formulated for delayed and/or sustained release of CX-8998 and about 60% of the second component that is formulated for immediate release of CX-8998.

30. The pharmaceutical composition according to claim 28 , wherein the first component comprises particles coated with a pH-sensitive enteric polymer.

31. The pharmaceutical composition according to claim 22 , wherein the CX-8998 is present in an amount of from about 0.5% to about 10% by weight of the free base equivalent of CX-8998.

32. The pharmaceutical composition according to claim 22 , wherein CX-8998 is in the form of a hydrochloride salt.

Assignments (2)
SECURITY AGREEMENT Recorded Apr 21, 2026
From: CAVION, INC.; JAZZ PHARMACEUTICALS, INC.; JAZZ PHARMACEUTICALS IRELAND LIMITED; JAZZ PHARMACEUTICALS RESEARCH UK LIMITED; JAZZ PHARMACEUTICALS THERAPEUTICS, INC.
To: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE
Reel/Frame 075442/0203 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 23, 2021
From: LEE, MARGARET S.; PAPAPETROPOULOS, SPYRIDON; HIGGIN, MICHELLE S.; DUVVURI, MURALIKRISHNA; REHLAENDER, BRUCE N.; NEWBOLD, EVAN
To: CAVION, INC.
Reel/Frame 056966/0001 →
Continuity (3)
Provisional Application 62780049 · Dec 14, 2018
Provisional Application 62740755 · Oct 3, 2018
Related Publication 20220016095A1 · Jan 20, 2022
References Cited (215)
US 4808605A · Branca et al. · 1989 [cited by applicant]
US 6451991B1 · Martin et al. · 2002 [cited by applicant]
US 7112319B2 · Broderick et al. · 2006 [cited by applicant]
US 7319098B2 · Cho et al. · 2008 [cited by applicant]
US 7875636B2 · Barrow · 2011 [cited by applicant]
US 8133998B2 · Pajouhesh et al. · 2012 [cited by applicant]
US 8263627B2 · Barrow · 2012 [cited by applicant]
US 8586619B2 · Wu et al. · 2013 [cited by applicant]
US 8637513B2 · Barrow · 2014 [cited by applicant]
US 8916743B2 · Ohmori et al. · 2014 [cited by applicant]
US 10292989B2 · Jevtovic-todorovic et al. · 2019 [cited by applicant]
US 11311522B1 · Lee et al. · 2022 [cited by applicant]
US 20010049447A1 · Li et al. · 2001 [cited by applicant]
US 20030158143A1 · Gleave et al. · 2003 [cited by applicant]
US 20040198822A1 · Fraser · 2004 [cited by applicant]
US 20050245535A1 · Hangeland et al. · 2005 [cited by applicant]
US 20060003985A1 · Renger et al. · 2006 [cited by applicant]
US 20080293786A1 · Hahn et al. · 2008 [cited by applicant]
US 20090270413A1 · Galemmo, Jr. et al. · 2009 [cited by applicant]
US 20090325979A1 · Choi et al. · 2009 [cited by applicant]
US 20100004286A1 · Cho et al. · 2010 [cited by applicant]
US 20100056545A1 · Shin et al. · 2010 [cited by applicant]
US 20100094006A1 · Nam et al. · 2010 [cited by applicant]
US 20100137403A1 · Malstrom et al. · 2010 [cited by applicant]
US 20100151022A9 · Lenaerts · 2010 [cited by applicant]
US 20100216841A1 · Barrow et al. · 2010 [cited by applicant]
US 20140004186A1 · Hustvedt · 2014 [cited by applicant]
US 20140155444A1 · Tung et al. · 2014 [cited by applicant]
US 20170189342A1 · Nguyen et al. · 2017 [cited by applicant]
US 20180280357A1 · Maricich · 2018 [cited by applicant]
US 20200163943A1 · Maricich et al. · 2020 [cited by applicant]
US 20200197377A1 · Maricich · 2020 [cited by applicant]
CN 102695506A · 2012 [cited by applicant]
EP 1757590B1 · 2009 [cited by applicant]
EP 1568695B1 · 2016 [cited by applicant]
KR 20090044924A · 2009 [cited by applicant]
KR 101679262B1 · 2016 [cited by applicant]
WO 1993004047A1 · 1993 [cited by applicant]
WO 2004003500A1 · 2004 [cited by applicant]
WO 2005007124A2 · 2005 [cited by applicant]
WO 2005009392A2 · 2005 [cited by applicant]
WO 2005007124A3 · 2005 [cited by applicant]
WO 2006023881A2 · 2006 [cited by applicant]
WO 2006023883A2 · 2006 [cited by applicant]
WO 2005009392A3 · 2006 [cited by applicant]
WO 2006023883A3 · 2006 [cited by applicant]
WO 2006098969A2 · 2006 [cited by applicant]
WO 2007002361A2 · 2007 [cited by applicant]
WO 2007002884A2 · 2007 [cited by applicant]
WO 2007007852A1 · 2007 [cited by applicant]
WO 2006098969A3 · 2007 [cited by applicant]
WO 2007002361A3 · 2007 [cited by applicant]
WO 2007002884A3 · 2007 [cited by applicant]
WO 2007073497A2 · 2007 [cited by applicant]
WO 2007120729A3 · 2008 [cited by applicant]
WO 2008007835A1 · 2008 [cited by applicant]
WO 2008018655A1 · 2008 [cited by applicant]
WO 2008033447A1 · 2008 [cited by applicant]
WO 2008033456A1 · 2008 [cited by applicant]
WO 2008033460A2 · 2008 [cited by applicant]
WO 2008033465A1 · 2008 [cited by applicant]
WO 2008033464A3 · 2008 [cited by applicant]
WO 2008050200A1 · 2008 [cited by applicant]
WO 2008110008A1 · 2008 [cited by applicant]
WO 2008117148A1 · 2008 [cited by applicant]
WO 2009009015A1 · 2009 [cited by applicant]
WO 2006023881A3 · 2009 [cited by applicant]
WO 2009054982A1 · 2009 [cited by applicant]
WO 2009054983A1 · 2009 [cited by applicant]
WO 2009054984A1 · 2009 [cited by applicant]
WO 2009035307A3 · 2009 [cited by applicant]
WO 2009056934A1 · 2009 [cited by applicant]
WO WO2009133128A1 · 2009 [cited by applicant]
WO 2009146540A1 · 2009 [cited by applicant]
WO 2009146539A8 · 2010 [cited by applicant]
WO 2010083264A1 · 2010 [cited by applicant]
WO 2010141842A2 · 2010 [cited by applicant]
WO WO2011093393A1 · 2011 [cited by applicant]
WO 2011019262A3 · 2011 [cited by applicant]
WO 2012094615A2 · 2012 [cited by applicant]
WO 2013169857A1 · 2013 [cited by applicant]
WO 2014110409A2 · 2014 [cited by applicant]
WO 2016203239A1 · 2016 [cited by applicant]
WO WO2016187718A1 · 2016 [cited by applicant]
WO WO2017044578A1 · 2017 [cited by applicant]
WO 2017070680A1 · 2017 [cited by applicant]
WO WO2017058353A1 · 2017 [cited by applicant]
WO WO2017117569A1 · 2017 [cited by applicant]
WO 2018200844A1 · 2018 [cited by applicant]
WO 2018200850A1 · 2018 [cited by applicant]
WO 2019175395A1 · 2019 [cited by applicant]
WO 2020072773A9 · 2020 [cited by applicant]
WO 2021067697A1 · 2021 [cited by applicant]
Ashford, S. et al. (2006), “Goal Attainment For Spasticity Management Using Botulinum Toxin,” Physiotherapy Research International 11(1):24-34. [cited by applicant]
Bailus, B.J. et al. (Jun. 2014). “The Prospect Of Molecular Therapy For Angelman Syndrome And Other Monogenic Neurologic Disorders,” BMC Neurosci. 15(1):76, 7 pages. [cited by applicant]
Bain, P.G. et al. (1993). “Assessing Tremor Severity,” Journal of Neurology, Neurosurgery & Psychiatry 56 (8):868-873. [cited by applicant]
Bermejo-Pareja, F. (2011, e-pub Apr. 12, 2011). “Essential Tremor—A Neurodegenerative Disorder Associated With Cognitive Defects?” Nature Reviews Neurology 7(5):273-282. [cited by applicant]
Bermejo-Pareja, F. et al. (Sep. 14, 2012). “Cognitive Features Of Essential Tremor: A Review Of The Clinical Aspects And Possible Mechanistic Underpinnings,” Tremor And Other Hyperkinetic Movements 2:13 pages. [cited by applicant]
Bezençon, O et al. (2017). “Milestones To The Discovery Of T-Type Calcium Channel Blockers For The Treatment Of Generalized Epilepsies,” CHIMIA International Journal for Chemistry 71(10):722-729. [cited by applicant]
Blom, K.F. et al. (Nov. 8, 2004). “Preparative LC-MS Purification: Improved Compound Specific Method Optimization,” J Comb. Chem. 6(6):874-883. [cited by applicant]
Bourinet, E. et al. (Jan. 26, 2005). “Silencing Of The Cav3.2 T-Type Calcium Channel Gene In Sensory Neurons Demonstrates Its Major Role In Nociception,” EMBO J. 24(2):315-324. [cited by applicant]
Carter, P. et al. (May 1992). “Humanization of an Anti-p185HER2 Antibody for Human Cancer Therapy,” Proc. Natl. Acad. Sci. USA 89:4285-4289. [cited by applicant]
Casillas-Espinosa, P.M. et al. (Aug. 14, 2015). “Z944, A Novel Selective T-Type Calcium Channel Antagonist Delays The Progression Of Seizures In The Amygdala Kindling Model,” PLOS One 10(8):e0130012, 1-12. [cited by applicant]
Cech, T.R. (Nov. 25, 1988). “Ribozymes And Their Medical Implications,” JAMA 260(20):3030-3034. [cited by applicant]
Chandran, V. et al. (2012). “Non-Motor Features In Essential Tremor,” Acta Neurologica Scandinavica 125 (5):332-337. [cited by applicant]
clinicaltrials.gov (Apr. 5, 2017). “A Phase 2 RCT Study of CX-8998 for Essential Tremor,” clinicaltrials.gov No. NCT03101241, 8 pages, retrieved from https://clinicaltrials.gov/ct2/show/NCT03101241. [cited by applicant]
Cribbs, L.L. et al. (Jul. 13, 1998). “Cloning And Characterization Of Alpha1h From Human Heart, A Member Of The T-Type Ca2+ Channel Gene Family,” Circulation Research 83(1):103-109. [cited by applicant]
Elbe, R. et al. (2013, e-pub Sep. 3, 2013). “Task Force Report: Scales For Screening And Evaluating Tremor: Critique And Recommendations,” Movement Disorders 28(13):1793-1800. [cited by applicant]
Elble, R. et al. (Jun. 26, 2008). “1094 The Essential Tremor Rating Assessment Scale (TETRAS),” Mov Disord. 23 (Suppl 1):S357. [cited by applicant]
Elble, R. et al. (Oct. 2012). “Reliability Of A New Scale For Essential Tremor,” Movement Disorders 27 (12):1567-1569, 10 pages. [cited by applicant]
Elble, R.J. et al. (Jan. 1996). “Quantification Of Essential Tremor In Writing And Drawing,” Movement Disorders: Official Journal Of The Movement Disorder Society 11(1):70-78. [cited by applicant]
Ertel, E.A et al. (Mar. 2000). “Nomenclature Of Voltage-Gated Calcium Channels,” Neuron 25(3):533-535. [cited by applicant]
Fahn, S. et al. (1987). Recent Developments in Parkinson's Disease 2:153-163 and 293-304, 8 pages, as retrieved on May 21, 2021 from https://www.parkinsons.va.gov/resources/UPDRS.asp. [cited by applicant]
Fahn, S. et al. (1988). “Clinical Rating Scale For Tremor,” Parkinson's Disease And Movement Disorders 2:225-234. [cited by applicant]
Flatters, S.J.L. (Jun. 1, 2005). “T-Type Calcium Channels: A Potential Target For The Treatment Of Chronic Pain,” Drugs Future 30(6):573-580. [cited by applicant]
Gadde, K.M. et al. (Aug. 15, 2007). “Combination Therapy Of Zonisamide And Bupropion For Weight Reduction In Obese Women: A Preliminary, Randomized, Open-Label Study,” Journal of Clinical Psychiatry 68(8):1226-1229. [cited by applicant]
George, M.S. et al. (Dec. 1994). “Social Phobia Secondary To Physical Disability: A Review Of Benign Essential Tremor (BET) And Stuttering,” Psychosomatics 35(6):520-523, 7 pages. [cited by applicant]
Giordanetto, F. et al. (Jan. 1, 2011). “T-Type Calcium Channels Inhibitors: A Patent Review,” Expert Opin. Ther. Pat. 21(1):85-101. [cited by applicant]
Handforth, A. et al. (2005). “Pharmacologic Evidence for Abnormal Thalamocortical Functioning in GABAA Receptor β3 Subunit-Deficient Mice, a Model of Angelman Syndrome,” Epilepsia 46(12):1860-1870. [cited by applicant]
Hanyu, H. (2007). “Nilvadipine Prevents Cognitive Decline In Patients With Mild Cognitive Impairment,” Intl J Geriatr Psychiatry 22:1264-1266. [cited by applicant]
Haseloff, J. et al. (Aug. 1988). “Simple RNA Enzymes With New And Highly Specific Endoribonuclease Activities,” Nature 334(6183):585-591. [cited by applicant]
Haubenberger, D. et al. (Sep. 2016). “Transducer-Based Evaluation Of Tremor,” Movement Disorders 31 (9):1327-1336, 21 pages. [cited by applicant]
Hoffman, J.D. et al. (Aug. 30, 2011-Sep. 3, 2011). “Objective Measure Of Upper Extremity Motor Impairment In Parkinson's Disease With Inertial Sensors,” Conf Proc IEEE Eng Med Biol Soc., 4378-4381. [cited by applicant]
Huang, H.-S. et al. (Jan. 2012). “Topoisomerase Inhibitors Unsilenced The Dormant Allele Ofube3a In Neurons”, Nature 481(7380):185-189, 14 pages. [cited by applicant]
Huguenard, J.R. et al. (Sep. 1, 1994). “Intrathalamic Rhythmicity Studied In Vitro: Nominal T-Current Modulation Causes Robust Antioscillatory Effects,” J Neuroscience 14(9):5485-5502. [cited by applicant]
Iannetti, P. et al. (Jul. 1, 2009, e-pub. Mar. 2009). Addition Of Verapamil In The Treatment Of Severe Myoclonic Epilepsy In Infancy, Epilepsy Research 85(1):89-95. [cited by applicant]
Iftinca, M.C. et al. (2009, e-pub. Nov. 29, 2008). “Regulation Of Neuronal T-Type Calcium Channels,” Trends In Pharmacological Sciences 30(1):32-40. [cited by applicant]
Iinuma, K et al. (Dec. 1, 2004). “Clinical Efficacy Of Zonisamide In Childhood Epilepsy After Long-Term Treatment: A Postmarketing, Multi-Institutional Survey,” Seizure GB, 13:534-539. [cited by applicant]
International Preliminary Report on Patentability issue date of Oct. 29, 2019, for Patent Application No. PCT/US2018/029610, filed Apr. 26, 2018, 5 pages. [cited by applicant]
International Preliminary Report on Patentability issue date of Apr. 24, 2018 for Patent Application No. PCT/US2016/058487, filed Oct. 24, 2016, 6 pages. [cited by applicant]
International Preliminary Report on Patentability issue date of Oct. 29, 2019, for Patent Application No. PCT/US2018/029616, filed Apr. 26, 2018, 5 pages. [cited by applicant]
International Search Report and Written Opinion of the Searching Authority mailed Jul. 11, 2018, for Patent Application No. PCT/US2018/029616, filed Apr. 26, 2018, 7 pages. [cited by applicant]
International Search Report and Written Opinion of the Searching Authority mailed May 8, 2018, for Patent Application No. PCT/US2018/18356, filed Feb. 15, 2018, 9 pages. [cited by applicant]
International Search Report and Written Opinion of the Searching Authority mailed on Dec. 10, 2019, for Patent Application No. PCT/US2019/054498, 13 pages. [cited by applicant]
International Search Report and Written Opinion of the Searching Authority mailed on Jan. 3, 2017, for Patent Application No. PCT/US2016/058487, filed Oct. 24, 2016, 8 pages. [cited by applicant]
International Search Report and Written Opinion of the Searching Authority mailed on Jan. 13, 2021, for Patent Application No. PCT/US2020/053944, 8 pages. [cited by applicant]
International Search Report and Written Opinion of the Searching Authority mailed on Jul. 19, 2018, for Patent Application No. PCT/US2018/029610, filed Apr. 26, 2018, 7 pages. [cited by applicant]
Jefferies, A.C. et al. (Feb. 1989). “A Catalytic 13-Mer Ribozyme,” Nucleic Acids Res. 17(4):1371-1377. [cited by applicant]
Jiang, Y.-H., et al. (Oct. 1998). “Mutation Of The Angelman Ubiquitin Ligase In Mice Causes Increased Cytoplasmic P53 And Deficits Of Contextual Learning And Long-Term Potentiation,” Neuron 21(4):799-811. [cited by applicant]
Jinnah, H. et al. (2020). “Efficacy and Safety of CX-8998 in T-CALM, a Randomized, Double-Blind, Placebo-Controlled, Phase 2a Trial in Participants With Essential Tremor: Subgroup Analysis by Baseline Tremor Severity,” … [cited by applicant]
Jinnah, H.A. et al. (2020). “Efficacy And Safety Of CX-8998 In T-Calm, A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Trial In Participants With Essential Tremor: Subgroup Analysis By Baseline Tremor Severity,… [cited by applicant]
Jinnah, H.A. et al. (Apr. 14, 2020). “Efficacy And Safety Of CX-8998 In T-CALM, A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Trial In Participants With Essential Tremor: Subgroup Analysis By Baseline Tremor … [cited by applicant]
Jinnah, H.A. et al. (Sep. 2020). “Efficacy And Safety Of CX-8998 In T-CALM, A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Trial In Participants With Essential Tremor: Subgroup Analysis By Baseline Tremor Seve… [cited by applicant]
Jones, P. et al. (May 29, 1986). “Replacing The Complementarity-Determining Regions In A Human Antibody With Those From A Mouse,” Nature 321:522-525. [cited by applicant]
Kamper, S.J. et al. (2009). “Global Rating Of Change Scales: A Review Of Strengths And Weaknesses And Considerations For Design,” Journal of Manual & Manipulative Therapy 17(3):163-170. [cited by applicant]
Keened, L. et al. (1989). “Flunarizine As A Supplementary Medication In Refractory Childhood Epilepsy A Double-Blind Crossover Study”, Canadian Journal Of Neurological Sciences 16(2):191-193. [cited by applicant]
Khan, F. et al. (Apr. 2008). “Use Of Goal Attainment Scaling In Inpatient Rehabilitation For Persons With Multiple Sclerosis,” Archives Of Physical Medicine And Rehabilitation 89(4):652-659. [cited by applicant]
Kim, S.-H. et al. (Dec. 1987). “Three-Dimensional Model Of The Active Site Of The Self-Splicing Rrna Precursor Of Tetrahymena,” Proc. Natl. Acad. Sci. USA 84(24):8788-8792. [cited by applicant]
Kiresuk, T.J. et al. (1968). “Goal Attainment Scaling: A General Method For Evaluating Comprehensive Community Mental Health Programs,” Community Mental Health Journal 4(6):443-453. [cited by applicant]
Lee, J,-H. et al. (Mar. 15, 1999). “Cloning And Expression Of A Novel Member Of The Low Voltage-Activated T-Type Calcium Channel Family,” Journal of Neuroscience 19(6):1912-1921. [cited by applicant]
Lee, M. (2019). “The Biology Of Pathological Oscillations In The Brain: Potential Novel Targets For Tremor Disorders,” International Congress of Parkinson's Disease and Movement Disorders, Nice, France, Sep. 22-26, 2019… [cited by applicant]
Lee, M. et al. (Apr. 9, 2018). Reversal Of Allodynia And Neurophysiological Outcomes By CX-8998, A Potent, 1-3 Selective T-Type Calcium Channel Modulator, In A Model Of Bortezomib Induced Peripheral Neurotoxicity (S7.00… [cited by applicant]
Lee, M.S. et al. (2018). “Therapeutic Exposures of CX-8998, A Potent, Selective and State Dependent T-type Calcium Channel (Cav3) Antagonist with Dose Dependent Efficacy in Cav3 Driven Neurological Models,” Mov Disord. … [cited by applicant]
Lee, M.S. et al. (2018). “Therapeutic Exposures of CX-8998, A Potent, Selective Cav3 Channel Antagonist With Dose Dependent Efficacy in Cav3 Driven Neurological Models,” Neurotherapeutics 15:830, Poster #31 presented at… [cited by applicant]
Llinás, R.R. (2003). “Thalamo-Cortical Dysrhythmia Syndrome: Neuropsychiatric Features,” An R Acad Nac Med (Madr). 120(2):267-290, 52 pages, English Translation. [cited by applicant]
Llinás, R.R. et al. (2007). “y-Band Deficiency And Abnormal Thalamocortical Activity In P/Q-Type Channel Mutant Mice,” Proceedings of the National Academy of Sciences 104(45):17819-17824. [cited by applicant]
Long, M.A. et al. (Dec. 15, 2002). “Rhythmicity Without Synchrony In The Electrically Uncoupled Inferior Olive,” Journal of Neuroscience 22(24):10898-10905. [cited by applicant]
Lopez, S.J. et al. (Jan. 4, 2019). “UBE3A: An E3 Ubiquitin Ligase With Genome-Wide Impact In Neurodevelopmental Disease,” Frontiers In Molecular Neuroscience, 11(476):1-8. [cited by applicant]
Lorenz, D. et al. (2006). “Quality Of Life And Personality In Essential Tremor Patients,” Movement Disorders: Official Journal Of The Movement Disorder Society 21(8):1114-1118. [cited by applicant]
Louis, E.D. (Oct. 2000). “Essential Tremor,” Arch Neurol. 57(10):1522-1524, 5 pages. [cited by applicant]
Louis, E.D. et al. (1998). “How Common Is The Most Common Adult Movement Disorder? Estimates Of The Prevalence Of Essential Tremor Throughout The World,” Movement Disorders: Official Journal Of The Movement Disorder Soc… [cited by applicant]
Louis, E.D. et al. (2010). “How Common Is The Most Common Adult Movement Disorder? Update On The Worldwide Prevalence Of Essential Tremor,” Movement Disorders 25(5):534-541. [cited by applicant]
Louis, E.D. et al. (Jul. 2015). “Tremor-Related Quality Of Life: A Comparison Of Essential Tremor Vs. Parkinson's Disease Patients.” Parkinsonism & Related Disorders 21(7):729-735, 20 pages. [cited by applicant]
Maricich, Y. et al. (2017). “TETRAS Applicability and Study Design in Randomized, Placebo Controlled Clinical Evaluation of Cav3 modulation for patients with essential tremor,” Mov Disord. 32(suppl 2):S296, Poster prese… [cited by applicant]
McGivern, J.G. (Mar. 2006). “Targeting N-Ty1)E And T-Ty1)E Calcium Channels For The Treatment Of Pain,” Drug Discovery Today 11(5-6):245-253. [cited by applicant]
Miller, A.R. et al. (Feb. 2014). “Mapping Genetic Modifiers Of Survival In A Mouse Model of Dravet Syndrome,” Genes Brain Behav. 13(2):163-172. [cited by applicant]
Mitsi, G. et al. (Jun. 13, 2017). “Biometric Digital Health Technology For Measuring Motor Function In Parkinson's Disease: Results From A Feasibility And Patient Satisfaction Study,” Frontiers In Neurology 8:273, 5 pag… [cited by applicant]
Molineux, M.L. et al. (Apr. 4, 2006). “Specific T-Type Calcium Channel Isoforms Are Associated With Distinct Burst Phenotypes In Deep Cerebellar Nuclear Neurons,” Proc Natl Acad Sci USA 103(14):5555-5560. [cited by applicant]
Mostile, G. et al. (2010). “Correlation Between Kinesia System Assessments And Clinical Tremor Scores In Patients With Essential Tremor,” Movement Disorders 25(12):1938-1943. [cited by applicant]
Nicoll, R.A. (Jan. 18, 2017). “A Brief History Of Long-Term Potentiation,” Neuron 93(2):281-290. [cited by applicant]
Nolt, D.H. et al. (Dec. 15, 2003). “Assessment Of Anticonvulsant Effectiveness And Safety In Patients With Angelman's Syndrome Using An Internet Questionnaire,” American Journal Of Health-System Pharmacy 60(24):2583-258… [cited by applicant]
Odgerel, Z. et al. (2019, e-pub. Jan. 16, 2018). “Whole Genome Sequencing And Rare Variant Analysis In Essential Tremor Families,” PloS One 14(8):e0220512. [cited by applicant]
Ondo, W. et al. (2020). “Efficacy and Safety of the T-Type Calcium Channel Modulator CX-8998 in T-CALM, a Randomized, Double-Blind, Placebo-Controlled, Phase 2a Trial in Participants with Essential Tremor,” Annals of Ne… [cited by applicant]
Ondo, W. et al. (2020). “Efficacy and Safety of the T-Type Calcium Channel Modulator CX-8998 in T-CALM, a Randomized, Double-Blind, Placebo-Controlled, Phase 2a Trial in Participants With Essential Tremor,” Annual Meeti… [cited by applicant]
Papapetropoulos, S. et al. (2008). “A Questionnaire-Based (UM-PDHQ) Study Of Hallucinations In Parkinson's Disease,” BMC Neurology 8(1):1-8. [cited by applicant]
Papapetropoulos, S. et al. (2018). “A Novel, State-dependent Cav3 Channel Antagonist in Phase 2 Development for Tremor and Epilepsy,” Neurotherapeutics 15:832, Poster presented at American Society for Experimental Neuro… [cited by applicant]
Papapetropoulos, S. et al. (2018). “A Phase 2 Efficacy Study of an Oral, Potent and Selective T-Type Calcium (Cav3) Modulator in Essential Tremor Patients (T-CALM): Design and Dose Selection Rationale,” Neurology. 2018;… [cited by applicant]
Papapetropoulos, S. et al. (2018). “A Proof-of-Principle Quantitative EEG Study of an Oral, Potent and Selective T-Type Calcium Modulator in Healthy Volunteers,” 90(suppl 15):P4.261, Poster presented at American Academy… [cited by applicant]
Papapetropoulos, S. et al. (2018). “Proof-of-Principle Quantitative EEG Study of CX-8998, an Oral, Potent and Selective T-Type Calcium Antagonist in Development for Symptomatic Treatment of Essential Tremor and Parkinso… [cited by applicant]
Papapetropoulos, S. et al. (2019). “Efficacy Results From A Phase 2, Double-Blind, Placebo-Controlled Study Of CX-8998 A State-Dependent T-Type Calcium (Cav3) Channel Modulator In Essential Tremor Patients (T-CALM),” Am… [cited by applicant]
Papapetropoulos, S. et al. (Jun. 11, 2019). “A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Of CX-8998, A Selective Modulator Of The T-Type Calcium Channel In Inadequately Treated Moderate To Severe Essen… [cited by applicant]
Papapetropoulos, S. et al. (Mar. 25, 2021). “A Phase 2 Proof-of-Concept, Randomized, Placebo-Controlled Trial of CX-8998 in Essential Tremor,” Mov Disord., 8 pages. [cited by applicant]
Park, Y-G. et al. (2010). “Cav3.1 Is A Tremor Rhythm Pacemaker In The Inferior Olive,” Proceedings Of The National Academy of Sciences 107(23):10731-10736. [cited by applicant]
Park, Y-G. et al. (2013). “The Potential Roles Of T-Type Ca2+ Channels In Motor Coordination,” Frontiers In Neural Circuits 7:172, 11 pages. [cited by applicant]
Pasek, J.G. et al. (Sep. 2015, e-pub Sep. 1, 2016). “Differential Camkii Regulation By Voltage-Gated Calcium Channels In The Striatum,” Mol. Cell. Neurosci. 68:234-243, 26 pages. [cited by applicant]
Perez-Reyes, E. (1998). “Molecular Characterization Of A Novel Family Of Low Voltage-Activated, T-Type, Calcium Channels,” Journal Of Bioenergetics And Biomembranes 30(4):313-318. [cited by applicant]
Peturssion, S. et al. (Nov. 1997). “Protecting Groups in Carbohydrate Chemistry,” J Chem. Educ. 74(11):1297-1303. [cited by applicant]
Powell, K.L. et al. (May 2014, e-pub Jul. 9, 2013). “Low Threshold T-Type Calcium Channels As Targets For Novel Epilepsy Treatments, ” British Journal of Clinical Pharmacology 77(5):729-739. [cited by applicant]
Pubchem (Jun. 14, 2012). “[(IS,2S)-6-Fluoro-2-[2-[methyl-[5-(1-methlybenzimidazol-2-yl)pently]-1-propan-2-yl-3,4-dihydro-1H-naphthalen-2-yl] N-butylcarbamate,” CID 57173592, 10 pages, as retrieved on http://pubchem.ncbi… [cited by applicant]
Pulliam, C.L. et al. (2014). “Continuous In-Home Monitoring Of Essential Tremor,” Parkinsonism & Related Disorders 20(1):37-40. [cited by applicant]
Radin, M.J. et al. (Nov. 1993). “Treatment of Obese Female and Male SHHF/Mcc-facp Rats with Antihypertensive Drugs, Nifedipine and Enalapril: Effects on Body Weight, Fat Distribution, Insulin Resistance and Systolic Pre… [cited by applicant]
Reger, T.S. et al. (2011, e-pub Jan. 26, 2011) “Pyridyl Amides As Potent Inhibitors Of T-Type Calcium Channels.” Bioorganic & Medicinal Chemistry Letters 21(6):1692-1696. [cited by applicant]
Riechmann, L. et al. (Mar. 24, 1988). “Reshaping Human Antibodies for Therapy,” Nature 33(6162):323-327. [cited by applicant]
Siegrist, R. et al. (2016). “Structure-Activity Relationship, Drug Metabolism And Pharmacokinetics Properties Optimization, And In Vivo Studies Of New Brain Penetrant Triple T-Type Calcium Channel Blockers.” Journal Of … [cited by applicant]
Silva-Santos, S. et al. (May 2015). “Ube3a Reinstatement Identifies Distinct Developmental Windows In A Murine Angelman Syndrome Model,” J. Clin. Invest. 125(5):2069-2076. [cited by applicant]
Sims, M.J. et al. (Aug. 15, 1993). “A Humanized CD18 Antibody Can Block Function Without Cell Destruction,” J. Immunol. 151(4):2296-2308. [cited by applicant]
So-Hee, E. et al. (Apr. 1, 2011). “Comparative Trial Of Low- And High-Dose Zonisamide As Monotherapy For Childhood Epilepsy”, Seizure 20(7):558-563. [cited by applicant]
Still, W.C. et al. (Jul. 1978). “Rapid Chromatographic Technique For Preparative Separations With Moderate Resolution,” The Journal of Organic Chemistry 43(14):2923-2925. [cited by applicant]
Tröster, A.I. et al. (2005). “Quality Of Life In Essential Tremor Questionnaire (QUEST): Development And Initial Validation.” Parkinsonism & Related Disorders 11(6):367-373. [cited by applicant]
U.S. Appl. No. 17/282,730, Lee et al., filed Apr. 2, 2021.(Not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii) issued by the Office on Sep. 21, 2004). [cited by applicant]
Verhoeyen, M. et al. (Mar. 25, 1988). “Reshaping Human Antibodies: Grafting An Antilysozyme Activity,” Science 239(4857):1534-1536. [cited by applicant]
Voller, B. et al. (Apr. 2014). “Alcohol Challenge And Sensitivity To Change Of The Essential Tremor Rating Assessment Scale,” Movement Disorders 29(4): 555-558, 10 pages. [cited by applicant]
Xiang, Z. et al. (Dec. 21, 2011, e-pub Oct. 17, 2011). “The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effect in STN Neurons and in a Rodent Model of … [cited by applicant]
Yamauchi, T. et al. (May 2005). “Neuronal Ca2+/Calmodulin-Dependent Protein Kinase II-Discovery, Progress In A Quarter Of A Century, And Perspective: Implication For Learning And Memory,” Biological and Pharmaceutical B… [cited by applicant]
Yaǧmur, I, et al. (May 28, 2016). “Benign Prostatic Hyperplasia: Case Report Of A 17-Year-Old,” Journal of Pediatric Urology 12(4):267-e1, 8 pages. (Abstract Only). [cited by applicant]
Zamponi, G.W. et al. (Oct. 2015). “The Physiology, Pathology, And Pharmacology Of Voltage-Gated Calcium Channels And Their Future Therapeutic Potential,” Pharmacological Reviews 67(4):821-870. [cited by applicant]
Zesiewicz, T.A. et al. (Nov. 8, 2011). “Evidence-Based Guideline Update: Treatment Of Essential Tremor: Report Of The Quality Standards Subcommittee Of The American Academy Of Neurology,” Neurology 77(19):1752-1755. [cited by applicant]
Didsbury, J. et al., Abstracts of 20th Annual ASENT Meeting, Neurotherapeutics, 15:819-835 (2018). [cited by applicant]
Egan, M.F. et al., Randomized controlled study of the T-type calcium channel antagonist MK-8998 for the treatment of acute psychosis in patients with schizophrenia, Hum. Psychopharmacol., 28(2):124-133 (2013). [cited by applicant]
Matsunaga, S. et al., Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis, PLoS One, 10(4):e0123289 (2015). [cited by applicant]
Miwa, H. and Kondo, T., T-type calcium channel as a new therapeutic target for tremor, Cerebellum, 10(3):563-569 (2011). [cited by applicant]
Nicita, F. et al., Efficacy of verapamil as an adjunctive treatment in children with drug-resistant epilepsy: a pilot study, Seizure, 23(1):36-40 (2014). [cited by applicant]
Plosker, G.L., Stiripentol : in severe myoclonic epilepsy of infancy (dravet syndrome), CNS Drugs, 26(11):993-1001 (2012). [cited by applicant]
Porter, V.R. et al., Frequency and characteristics of anxiety among patients with Alzheimer's disease and related dementias, J. Neuropsychiatry Clin. Neurosci., 15(2):180-186 (2003). [cited by applicant]
Zadionchenko, V.S., Use of Calcium Channel Blockers in Patients With Cardiovascular Pathology: Focus on Diltiazem, Consilium Medicum 17(5):54-63, Russian Language only, (2015). [cited by applicant]